Novartis International AG / Three Scientists to Receive Prestigious Novartis Prizes for Immunology at 15th International Congress of Immunology . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
-- The Basic Immunology Prize is awarded to Drs. Tim R. Mossman and Robert L. Coffman for their work in defining subsets of T helper cells that advanced the understanding of infectious, autoimmune and allergic diseases.
-- The Clinical Immunology Prize is awarded to Dr. James Allison for his work in understanding how cancers evade the immune system and developing therapies to help enhance the body's immune response to cancers.
Basel, June 17, 2013 - The Novartis Prizes for Immunology are awarded to three scientists for their groundbreaking research into the biology of immune system T cells that advanced the prevention and treatment of a variety of diseases. The Prize ceremony will take place at the 15(th) International Congress of Immunology in Milan, Italy on August 23, 2013.
The Novartis Prize for Basic Immunology 2013 is shared by Tim R. Mossman, Ph.D., Director of the Human Immunology Center at the University of Rochester and Robert L. Coffman, Ph.D., Vice President and Chief Scientific Officer at Dynavax.
While working together in the 1980s at DNAX Research Institute in Palo Alto, CA, they determined the distinct functions of two T-helper cell subsets - with Th1 playing a major role in cellular immunity critical for resistance to infections, whereas Th2 cells can induce allergic diseases. They also found that dysregulation of Th1 and Th2 cell functions was implicated in many immunological diseases.
"The fundamental discovery by Drs. Mossman and Coffman of the specific types of T cells that helped either cellular or humoral (antibody-mediated) immunity revolutionized our understanding of how the immune system works, and led to major advances in designing therapies for infectious, inflammatory and allergic diseases and in vaccine design, " said Dhaval Patel, Head, NIBR Europe and Global Head of Autoimmunity, Transplantation and Immunology.
The Novartis Prize for Clinical Immunology 2013 is awarded to James Allison, Ph.D., Chair of The University of Texas MD Anderson Cancer Center, Department of Immunology, for research that is thwarting cancer's ability to evade attack by the immune system.
In the 1990s his study in mice demonstrated that CTLA-4, a molecule expressed on T cells, blocks the body's natural immune response. An antibody he developed against CTLA-4 inhibits tumor growth in mice, and has evolved into Ipilimumab, a successful treatment for advanced-stage melanoma in humans.
"I admire Dr. Allison's vision, drive, and perseverance in testing his immunomodulatory approach in humans, which will positively impact many patients with cancer," said Patel. "His discovery has not only given us new tools, but a new way of thinking about fighting cancer."
About the Novartis Prizes for Immunology
Established in 1990, The Novartis Prizes for Immunology are awarded every three years for breakthrough contributions to the fields of basic and clinical immunology as judged by an independent panel of experts. Each of the two Prizes is endowed for 100,000 CHF. One fifth of each prize is awarded in personal recognition of exceptional individual achievements, while the remainder is intended to support the prize winner's research. The prizes were established both to honor outstanding research in the most challenging areas of immunology-based science and to increase interactions between scientists in academia and industry.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 129,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.
# # #
Novartis Media Relations
Central media line : +41 61 324 2200 Eric Althoff Mariellen Gallagher Novartis Global Media Relations Novartis Institutes for BioMedical Research +41 61 324 7999 (direct) +1 617 871 7665 (direct) +41 79 593 4202 (mobile) +1 617 909 9137 (mobile) email@example.com firstname.lastname@example.org
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact: email@example.com.
Novartis Investor Relations
Central phone: +41 61 324 7944 Samir Shah +41 61 324 7944 North America: Pierre-Michel Bringer +41 61 324 1065 Stephen Rubino +1 862 778 8301 Thomas Hungerbuehler +41 61 324 8425 Jill Pozarek +1 212 830 2445 Isabella Zinck +41 61 324 7188 Edwin Valeriano +1 212 830 2456
e-mail: e-mail: firstname.lastname@example.org email@example.com
Media release (PDF): http://hugin.info/134323/R/1709714/566696.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Novartis International AG via Thomson Reuters ONE
--- End of Message ---
Novartis International AG
P.O. Box Basel Switzerland
WKN: 904278;ISIN: CH0012005267;
http://www.novartis.com (END) Dow Jones Newswires
June 17, 2013 01:16 ET (05:16 GMT)- - 01 16 AM EDT 06-17-13
||JB Tracker-Zertifikat auf den Global Infrastructure Basket|
||Vontobel: Schweizer Blue Chips: 6% p.a. garantiert inkl. 50% Sicherheitspuffer|
||Neu in Zeichnung: Bonus-Zertifikat Nestlé, Roche, Novartis | Bonus-Level 123% | Partizipation 100% | Barriere 69% | 2.5 Jahre Laufzeit|
||INDEXMONITOR: Heikle Chart-Situation beim SMI|
||Worst-Of BRC‘s auf Schweizer Bluechips und Europäische Grossunternehmen, Coupons von 11.6% und 15.6% p.a., Barrieren 60% und 50%, in CHF und EUR, Jetzt in Zeichnung|
||ideas Magazin - Oktober 2016|
|ABB verliert an Einnahmen und Ertrag|
|SMI und Dax schliessen mit Verlusten -- Dow-Index endet leicht im Plus -- UBS einigt sich mit Libor-Klägern -- Finanzplatz Schweiz legt zu --|
|Nokia überrascht mit Umsatzstärke|
|SMI und Dax stabil -- Belgiens Premier Michel: Einigung zu Ceta -- ABB verliert an Einnahmen und Ertrag -- Sika: Rekordgewinn -- Deutsche Bank mit schwarzen Quartalszahlen --|
|Schweizer Börse setzt Verlustserie fort|
|Kursverluste an Schweizer Börse ausgebaut|
|Partners Group - Was für ein Chart!|
|Roche bestätigt höhere Dividende|
|Deutsche Bank überrascht mit Gewinn|
|SMI: Weitere Abgaben erwartet|